US11028090, Example 493 4-(7- imidazole- 1-yl-1- methyl- [1,2,4]triazolo[4,3- a]quinoxaline- 4-ylamino)- butyl]- carbamic acid isobutylester
SMILES: CC(C)COC(=O)NCCCCNc1nc2cc(ccc2n2c(C)nnc12)-n1ccnc1
InChI Key: InChIKey=QKQHDZIZNMWRFA-UHFFFAOYSA-N
Data: 1 IC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bromodomain-containing protein 4 (Homo sapiens (Human)) | BDBM502566 (4-(7- imidazole- 1-yl-1- methyl- [1,2,4]triazolo[4...) | PDB KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 5 | n/a | n/a | n/a | n/a | n/a | n/a |
Dong Wha Pharm. Co., Ltd.; Korea Research Institute of Chemical Technology US Patent | Assay Description The following experiment was performed to evaluate the ability of [1,2,4]triazolo[4,3-a]quinoxaline derivative of the present invention to inhibit th... | US Patent US11028090 (2021) | |||||||||||
More data for this Ligand-Target Pair |